This data‑driven white paper analyzes the 340B rebate model, cash flow, and interest costs using real‑world pricing data for 10 drugs subject to Maximum Fair Price (MFP) in 2026.

Using rigorous modeling and updated list price reductions, these findings show that rebate‑related interest costs are marginal at best for disproportionate share (DSH) hospitals, non DSH hospitals, and federal grantees.

Download the white paper to get evidence‑based clarity on what the numbers actually say -- not the headlines -- on 340B drug pricing policy and rebate economics.